Adze-1.17.C.4.35

Adze-1.17.C.4.35 is a preclinical, oncolytic immunotherapy product developed by Adze Biotechnology, Inc., designed for the treatment of various solid tumors including colorectal cancer, ovarian cancer, and prostatic cancer[1][3][4]. It is part of the Adze-1.17 oncolytic virus platform and targets CD46 (membrane cofactor protein), functioning as a CD46 inhibitor[1]. The platform is engineered for systemic or intra-tumoral delivery of immune-stimulatory transgenes and checkpoint inhibitors to stimulate anti-tumor immune responses in neoplasms and other difficult-to-treat cancers[2]. The drug has not yet reached clinical trial phases beyond preclinical development.